Long-term safety and efficacy of teriflunomide

Paul O'Connor, Giancarlo Comi, Mark S. Freedman, Aaron E. Miller, Ludwig Kappos, Jean Pierre Bouchard, Christine Lebrun-Frenay, Jan Mares, Myriam Benamor, Karthinathan Thangavelu, Jinjun Liang, Philippe Truffinet, Victoria J. Lawson, Jerry S. Wolinsky

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). Methods: A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14 mg or 7 mg. Results: By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63%) remained on treatment. Teriflunomide was well-tolerated with continued exposure. The most common adverse events (AEs) matched those in the core study. In extension year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attributable to patients switching from placebo to teriflunomide. Approximately 11% of patients discontinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, remaining low thereafter. Disability remained stable in all treatment groups (median Expanded Disability Status Scale score ≤2.5; probability of 12-week disability progression ≤0.48). Conclusions: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide. Classification of evidence: This study provides Class III evidence that long-term treatment with teriflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term.

Original languageEnglish
Pages (from-to)920-930
Number of pages11
JournalNeurology
Volume86
Issue number10
DOIs
Publication statusPublished - Mar 8 2016

Fingerprint

Safety
Placebos
teriflunomide
Multiple Sclerosis
Therapeutics
Gadolinium
Hair
Recurrence
Liver
Enzymes

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Kappos, L., Bouchard, J. P., ... Wolinsky, J. S. (2016). Long-term safety and efficacy of teriflunomide. Neurology, 86(10), 920-930. https://doi.org/10.1212/WNL.0000000000002441

Long-term safety and efficacy of teriflunomide. / O'Connor, Paul; Comi, Giancarlo; Freedman, Mark S.; Miller, Aaron E.; Kappos, Ludwig; Bouchard, Jean Pierre; Lebrun-Frenay, Christine; Mares, Jan; Benamor, Myriam; Thangavelu, Karthinathan; Liang, Jinjun; Truffinet, Philippe; Lawson, Victoria J.; Wolinsky, Jerry S.

In: Neurology, Vol. 86, No. 10, 08.03.2016, p. 920-930.

Research output: Contribution to journalArticle

O'Connor, P, Comi, G, Freedman, MS, Miller, AE, Kappos, L, Bouchard, JP, Lebrun-Frenay, C, Mares, J, Benamor, M, Thangavelu, K, Liang, J, Truffinet, P, Lawson, VJ & Wolinsky, JS 2016, 'Long-term safety and efficacy of teriflunomide', Neurology, vol. 86, no. 10, pp. 920-930. https://doi.org/10.1212/WNL.0000000000002441
O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP et al. Long-term safety and efficacy of teriflunomide. Neurology. 2016 Mar 8;86(10):920-930. https://doi.org/10.1212/WNL.0000000000002441
O'Connor, Paul ; Comi, Giancarlo ; Freedman, Mark S. ; Miller, Aaron E. ; Kappos, Ludwig ; Bouchard, Jean Pierre ; Lebrun-Frenay, Christine ; Mares, Jan ; Benamor, Myriam ; Thangavelu, Karthinathan ; Liang, Jinjun ; Truffinet, Philippe ; Lawson, Victoria J. ; Wolinsky, Jerry S. / Long-term safety and efficacy of teriflunomide. In: Neurology. 2016 ; Vol. 86, No. 10. pp. 920-930.
@article{dca5441e5c554b10baae458e79ce55cc,
title = "Long-term safety and efficacy of teriflunomide",
abstract = "Objective: To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). Methods: A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14 mg or 7 mg. Results: By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63{\%}) remained on treatment. Teriflunomide was well-tolerated with continued exposure. The most common adverse events (AEs) matched those in the core study. In extension year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attributable to patients switching from placebo to teriflunomide. Approximately 11{\%} of patients discontinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, remaining low thereafter. Disability remained stable in all treatment groups (median Expanded Disability Status Scale score ≤2.5; probability of 12-week disability progression ≤0.48). Conclusions: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide. Classification of evidence: This study provides Class III evidence that long-term treatment with teriflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term.",
author = "Paul O'Connor and Giancarlo Comi and Freedman, {Mark S.} and Miller, {Aaron E.} and Ludwig Kappos and Bouchard, {Jean Pierre} and Christine Lebrun-Frenay and Jan Mares and Myriam Benamor and Karthinathan Thangavelu and Jinjun Liang and Philippe Truffinet and Lawson, {Victoria J.} and Wolinsky, {Jerry S.}",
year = "2016",
month = "3",
day = "8",
doi = "10.1212/WNL.0000000000002441",
language = "English",
volume = "86",
pages = "920--930",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Long-term safety and efficacy of teriflunomide

AU - O'Connor, Paul

AU - Comi, Giancarlo

AU - Freedman, Mark S.

AU - Miller, Aaron E.

AU - Kappos, Ludwig

AU - Bouchard, Jean Pierre

AU - Lebrun-Frenay, Christine

AU - Mares, Jan

AU - Benamor, Myriam

AU - Thangavelu, Karthinathan

AU - Liang, Jinjun

AU - Truffinet, Philippe

AU - Lawson, Victoria J.

AU - Wolinsky, Jerry S.

PY - 2016/3/8

Y1 - 2016/3/8

N2 - Objective: To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). Methods: A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14 mg or 7 mg. Results: By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63%) remained on treatment. Teriflunomide was well-tolerated with continued exposure. The most common adverse events (AEs) matched those in the core study. In extension year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attributable to patients switching from placebo to teriflunomide. Approximately 11% of patients discontinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, remaining low thereafter. Disability remained stable in all treatment groups (median Expanded Disability Status Scale score ≤2.5; probability of 12-week disability progression ≤0.48). Conclusions: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide. Classification of evidence: This study provides Class III evidence that long-term treatment with teriflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term.

AB - Objective: To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). Methods: A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14 mg or 7 mg. Results: By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63%) remained on treatment. Teriflunomide was well-tolerated with continued exposure. The most common adverse events (AEs) matched those in the core study. In extension year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attributable to patients switching from placebo to teriflunomide. Approximately 11% of patients discontinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, remaining low thereafter. Disability remained stable in all treatment groups (median Expanded Disability Status Scale score ≤2.5; probability of 12-week disability progression ≤0.48). Conclusions: In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide. Classification of evidence: This study provides Class III evidence that long-term treatment with teriflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term.

UR - http://www.scopus.com/inward/record.url?scp=84960471895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960471895&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002441

DO - 10.1212/WNL.0000000000002441

M3 - Article

AN - SCOPUS:84960471895

VL - 86

SP - 920

EP - 930

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -